仙琚制药（002332.SZ）11月5日在投资者互动平台表示，公司已于2025年4月制定并公告了市值管理制 度。市值管理工作由董事会领导、经营管理层共同参与。具体请参看相关公告。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：董秘你好公司有无建立市值管理制度？市值管理第一 责任人是谁？是否有考核奖惩措施？ ...

Core Viewpoint - Xianju Pharmaceutical (002332.SZ) confirmed that its major shareholder did not participate in the transfer and financing transactions on the investor interaction platform [1] Group 1 - The company clarified the involvement of its major shareholder in transfer and financing transactions [1]

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has announced that its product, injection vecuronium bromide, is proposed to be selected in the 11th national centralized drug procurement, which may enhance the product's accessibility and the company's brand influence [1][2]. Group 1: Product Selection Details - The company participated in the bidding for the 11th national centralized drug procurement from October 27 to 28, 2025 [1]. - The proposed selected product is injection vecuronium bromide, which passed the national consistency evaluation for generic drug quality and efficacy in December 2023 [2]. - The final selection price, quantity, and supply provinces will be based on the data released by the procurement office [1]. Group 2: Impact on Company - The sales revenue of injection vecuronium bromide for the year 2024 and the first nine months of 2025 has been reported, indicating a potential impact on the company's financial performance [2]. - The selected product's price will decrease compared to the original sales price, which is expected to improve drug accessibility and enhance the company's brand influence if procurement contracts are signed and implemented [2].

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first three quarters of 2025, indicating ongoing pressure on its performance [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 2.826 billion yuan, a year-on-year decrease of 12.71%, and a net profit attributable to shareholders of 407 million yuan, down 23.29% [2]. - The weighted average return on net assets was 6.8%, a decrease of 2.16 percentage points year-on-year, while the return on invested capital was 6.33%, down 2.22 percentage points compared to the same period last year [3]. Historical Performance Trends - The company has experienced a continuous decline in performance, with 2023 revenue falling by 5.85% to 4.123 billion yuan and net profit down 24.86% to 563 million yuan. In 2024, revenue further declined by 2.98% to 4.001 billion yuan, and net profit decreased by 29.46% to 397 million yuan [4]. - In the first half of 2025, revenue was 1.869 billion yuan, a year-on-year decrease of 12.56%, and net profit was 308 million yuan, down 9.26% [4]. Business Segment Analysis - The core revenue sources, both formulation and raw material drug businesses, are facing difficulties. In the first half of 2025, formulation sales revenue was 1.127 billion yuan, down 7.2%, while raw material and intermediate sales revenue was 730 million yuan, a decline of 20% [5]. - The company attributed its performance decline to the impact of national centralized procurement on products like dexamethasone sodium phosphate injection and the influence of provincial-level centralized procurement on common drugs like progesterone injection [5]. Regulatory Challenges - In 2025, the company faced dual regulatory challenges, including an "antitrust penalty" and "fundraising violations," which not only resulted in direct financial losses but also negatively impacted its market reputation [6]. - The Tianjin Market Supervision Administration imposed a fine totaling 195 million yuan for engaging in price-fixing agreements, which represented 4.88% of the company's audited revenue and 49.17% of its net profit attributable to shareholders for 2024 [7][8]. - Additionally, the Zhejiang Securities Regulatory Bureau issued a warning regarding issues in the management and use of raised funds, highlighting internal control weaknesses [9].

Company Overview - Xianju Pharmaceutical (SZ 002332) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office on October 27-28, 2025, with its product, Vecuronium Bromide Injection, expected to be selected for this procurement [1] Financial Performance - For the first half of 2025, Xianju Pharmaceutical's revenue composition was 99.34% from pharmaceuticals and 0.66% from other businesses [1]

Group 1 - Xianju Pharmaceutical's product, injection vecuronium bromide, is expected to be selected for the 11th batch of national centralized drug procurement, with sales revenue of 14.184 million yuan from January to September 2025, accounting for 0.5% of the company's total revenue during the same period. The selected price shows a certain degree of decline compared to the original sales price, which may enhance the accessibility of the product if the procurement contract is signed and implemented [1][1][1] Group 2 - Montai High-tech's "Montai Convertible Bonds" have their last conversion day on October 29. Investors holding these bonds can convert them before market close on that day. After market close, unconverted bonds will be forcibly redeemed at a price of 101.19 yuan per bond (including tax), which may lead to potential losses for investors [1][1][1] Group 3 - Tianhe Defense has submitted an application for a specific stock issuance to the Shenzhen Stock Exchange, which has been accepted [1][1][1]

Core Viewpoint - The company, Xianju Pharmaceutical (002332.SZ), announced its participation in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, indicating a strategic move to secure market presence and enhance sales for its product, Vecuronium Bromide injection [1] Group 1 - The company will participate in the bidding process from October 27 to October 28, 2025 [1] - The product, Vecuronium Bromide injection, is intended for use as an adjunct in general anesthesia, specifically for tracheal intubation and muscle relaxation during surgery [1] - The company aims to have its product selected in this centralized procurement, which could lead to increased market access and sales opportunities [1]

Core Viewpoint - The company, Xianju Pharmaceutical, announced its participation in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with its product, Vecuronium Bromide Injection, expected to be selected for this procurement [1] Group 1 - The procurement event is scheduled from October 27 to October 28, 2025 [1] - The product Vecuronium Bromide is primarily used as an adjunct in general anesthesia for tracheal intubation and muscle relaxation during surgery [1]

Core Viewpoint - The company participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement from October 27 to October 28, 2025, with its product, injection vecuronium bromide, expected to be selected in this procurement [1] Financial Performance - The sales revenue of injection vecuronium bromide for the year 2024 is projected to be 17.6915 million yuan, accounting for 0.44% of the company's total revenue for 2024 [1] - For the period from January to September 2025, the sales revenue reached 14.1840 million yuan, representing 0.50% of the company's total revenue for the same period [1]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-048 浙江仙琚制药股份有限公司 关于公司产品拟中选第十一批全国药品集中采购的公告 2、按照相关规定，采购周期内采购协议每年一签。续签采购协议时，约定采购量原则上不少于各地该 中选药品上年约定采购量。 二、本次产品拟中选对公司的影响 公司上述拟中选的注射用维库溴铵2024年度及2025年1-9月销售收入情况如 下： 1 药品 名称 适应症 剂型 /规 格 拟中选 价格 （元/瓶） 拟主供 省市 采购周期 注射用 维库溴 铵 主要作为全麻辅 助用药，用于全麻 时的气管插管及 手术中的肌肉松 弛。 粉针剂/4mg 2.24 江苏 浙江 陕西 吉林 黑龙江 辽宁 自中选结 果执行之 日起至 2028年12 月31日 一、 拟中选产品基本情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2025年10月27日至10 月28日参加了国家组织药品联合采购办公室（以下简称"联采办"）组织的第十 一批全国药品集中采购的投标工作。公司产品注射用维库溴铵拟中选本次集中 ...